Schneyer Mark C. 4

4 · ACADIA PHARMACEUTICALS INC · Filed May 5, 2026

AI-generated summary of this filing

Updated May 5, 2026

ACADIA CFO Mark Schneyer Sells 3,506 Shares After RSU Vesting

What Happened

Mark C. Schneyer, Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), had 6,815 restricted stock units (RSUs) convert to common shares on May 1, 2026 (reported as a derivative exercise/conversion). Those shares were used to satisfy tax withholding (reported as a $0.00 disposition). On May 4, 2026 he sold 3,506 shares in an open‑market transaction for a weighted average price of $21.79, generating proceeds of $76,396. This activity is primarily routine (vesting and tax withholding) with a subsequent open‑market sale.

Key Details

Transaction dates: RSU conversion and withholding — 2026-05-01; open‑market sale — 2026-05-04.
Sale price: weighted average $21.79 (range reported $21.79 to $21.7932); total proceeds ≈ $76,396.
Shares acquired via conversion: 6,815 RSUs converted to shares on 5/1 (footnote: each RSU = 1 share).
Shares disposed for withholding: 6,815 shares reported disposed at $0.00 to cover taxes (sell‑to‑cover / withholding).
Shares sold in market: 3,506 shares sold (open market).
Shares owned after transaction: not listed in the Form 4 provided.
Compliance notes: Mandatory withholding sale was made to cover taxes and is reported as intended to comply with Rule 10b5‑1; filing dated 2026-05-05 appears timely for the May 1–4 transactions.
Vesting schedule: RSUs vest in four equal annual installments beginning May 1, 2024 (per footnote).

Context

This was not a purchase signal — the primary events were RSU vesting and tax‑related withholding, followed by an open‑market sale of a portion of shares. For derivative/RSU transactions, a $0.00 disposition typically indicates shares were surrendered or withheld to pay taxes rather than sold for cash.

Form 4

Period: 2026-05-01

EVP, CHIEF FINANCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-01+6,815→ 69,651 total
Sale
Common Stock
[F2][F3]
2026-05-04$21.79/sh−3,506$76,396→ 66,145 total
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-05-01−6,815→ 6,815 total
→ Common Stock (6,815 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.7932, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
[F4]The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Signature

/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-05-05

1 file